Status: Recruiting
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
Participants needed: 383
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Beijing InnoCare Pharma Tech Co., Ltd.Updated: Feb 9, 2026Locations: 46
Eligibility criteria
Subjects voluntarily participate in this study and have signed informed consent. [+4]
The diagnosis was non-plaque psoriasis. [+9]